All In Biotech

Drug Trial Radar · NCT05719701

Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma

A Multi-center, Non-randomized, and Open-label Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Apr 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

80

Planned (sponsor's estimate)

Start

Mar 29, 2023

Primary completion

Jul 30, 2025

Study completion Dec 30, 2025

Sponsor

Sponsor type
Industry
First posted
Feb 9, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, non-randomized and open-label phase I/IIa clinical study to evaluate the safety, tolerability, and efficacy of ICP-490 in patients with relapsed and/or refractory multiple myeloma.

Conditions

  • Relapsed and/or Refractory Multiple Myeloma

Interventions

  • ICP-490Drug

    Several dose groups of ICP-490 are planned for the dose exploration.

  • DexamethasoneDrug

    Oral Dexamethasone is administered on Days 1, 8, 15, and 22 of each 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I : Incidence, type, and severity of adverse events (AEs) as judged according to NCI-CTCAE V5.0Time frame: Through study completion, an average of 3 years
  2. Phase I : Incidence, type, and severity of dose-limiting toxicities (DLTs)Time frame: Through study completion, an average of 3 years
  3. Phase I : RP2Ds and/or MTDsTime frame: Through study completion, an average of 3 years
  4. Phase II : ORR (defined as sCR + CR + VGPR + PR) assessed according to IMWG criteria.Time frame: Through study completion, an average of 3 years

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Not yet recruiting

  • Henan Cancer Hosptital

    Zhengzhou, Henan, China · Not yet recruiting

  • Shengjing Hospital of China Medical University

    Shenyang, Liaoning, China · Not yet recruiting

  • Renji Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • The First Affiliated Hospital,Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.